NCT05823870View on ClinicalTrials.gov

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 24, 2023

Primary Completion Date

March 6, 2023

Study Completion Date

March 20, 2023

Conditions

Healthy Subjects

Interventions

DRUG

DW6014

"Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast"

Trial Locations (1)

Unknown

Chungbuk National University Hospital, Cheongju-si